Posttraumatic Stress Disorder, Substance Use Disorders
Conditions
Brief summary
This project will provide initial feasibility and efficacy data for the implementation of Narrative Exposure Therapy (NET) to urban, at-risk youth. Posttraumatic stress and substance use outcomes, as well as participant responses to the intervention, will be examined.
Detailed description
The goal of the proposed study is to gather preliminary feasibility and efficacy data for an innovative intervention (Narrative Exposure Therapy: NET) to promote adolescent mental health related to interpersonal trauma (IPT). Among those at highest risk for interpersonal violence and its sequelae are youth from urban, low-resourced neighborhoods. Post-traumatic stress disorder (PTSD) is a common outcome associated with IPT. Substance misuse (SUB) is a frequent concomitant of PTSD. NET is a promising intervention to reduce PTSD symptoms and associated psychological distress, via the supported reconstruction (narrative telling) of the traumas. NET has a critical advantage over existing PTSD treatments in that it can be delivered in a brief format, in community settings where at-risk adolescents are likely to be found. Despite its promise in treating adolescent distress, NET has yet to be tested as an intervention for those who have interpersonal trauma-related PTSD. Further NET's influence on SUB has not been examined. Accordingly, the objective of this project is to conduct a pilot study (N=30) to estimate NET treatment effects on PTSD symptoms and SUB in IPT-exposed urban adolescents (ages 16-21). Both feasibility and preliminary efficacy data will be collected to serve as pilot work for a larger-scale NIH proposal. Recruitment and intervention will be set within community partners where the adolescents already are connected and are receiving social or psychological services. Outcome data will be collected at: (T0) Baseline, and at 1(T1), and 3 months (T2) follow-up assessments. Participant responses to the intervention will be assessed post-intervention. Change in PTSD, SUB will be estimated with effect sizes and inferential tests. Preliminary evidence of efficacy and feasibility will pave the way for further NET development to offer a patient-oriented, community-based, intervention that will promote adolescent mental health for those at greatest risk for health access and outcomes disparities.
Interventions
brief, trauma-focused treatment.
Sponsors
Study design
Eligibility
Inclusion criteria
* Adolescents (ages 16-25), * Positive PTSD diagnosis (CAPS diagnosis) * Positive lifetime incidence of interpersonal violence-related trauma.
Exclusion criteria
* Actively suicidal with an immediate referral to the community agency crisis staff * Severe cognitive delay * Active psychosis
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Posttraumatic Stress Disorder Checklist-Civilian Version | At baseline, at 1 month follow up, and at 3 month follow up | assessed via PTSD checklist. The minimum score for this measure is 0 while the maximum is 80. Higher scores indicate more severe PTSD symptoms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Alcohol Use Disorders Identification Test (AUDIT) | Only 1 participant finished the follow up for 1 month and 3 month (they are a different participant). | alcohol use assessed via AUDIT. The minimum score for this measure is 0 while the maximum is 40. Higher scores indicate more alcohol use. |
| Young Adult Alcohol Consequences Questionnaire (YAACQ) | Only 1 participant finished the follow up for 1 month and 3 month (they are a different participant). | alcohol consequences assessed via YAACQ. The minimum score for this measure is 0 while the maximum is 48. Higher scores indicate more alcohol consequences. |
Countries
United States
Contacts
University at Buffalo
Participant flow
Recruitment details
We recruited 50 participants for the phase 1 survey, 40 of them finished. We then recruited 74 participants into phase 2 and 60 completed the baseline (different participants than Phase 1). 1 Participant came back for the 1 month follow up. 9 participants came back for the 3 month follow up. 1 of them completed that follow up. The population this study used (homeless teens and young adults) made it extremely difficult to maintain contact so it was hard to follow up resulting in low numbers.
Baseline characteristics
| Characteristic | — |
|---|---|
| Age, Categorical Baseline (Phase 1) <=18 years | 16 Participants |
| Age, Categorical Baseline (Phase 1) >=65 years | 0 Participants |
| Age, Categorical Baseline (Phase 1) Between 18 and 65 years | 24 Participants |
| Age, Categorical Baseline (Phase 2) <=18 years | 11 Participants |
| Age, Categorical Baseline (Phase 2) >=65 years | 0 Participants |
| Age, Categorical Baseline (Phase 2) Between 18 and 65 years | 49 Participants |
| Age, Continuous Baseline (phase 1 and phase 2) | 18.95 years STANDARD_DEVIATION 2.51 |
| Age, Continuous Baseline (phase 2) | 19.66 years STANDARD_DEVIATION 2.35 |
| Race (NIH/OMB) Baseline (Phase 1) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Baseline (Phase 1) Asian | 0 Participants |
| Race (NIH/OMB) Baseline (Phase 1) Black or African American | 20 Participants |
| Race (NIH/OMB) Baseline (Phase 1) More than one race | 7 Participants |
| Race (NIH/OMB) Baseline (Phase 1) Native Hawaiian or Other Pacific Islander | 1 Participants |
| Race (NIH/OMB) Baseline (Phase 1) Unknown or Not Reported | 3 Participants |
| Race (NIH/OMB) Baseline (Phase 1) White | 9 Participants |
| Race (NIH/OMB) Baseline (Phase 2) American Indian or Alaska Native | 1 Participants |
| Race (NIH/OMB) Baseline (Phase 2) Asian | 0 Participants |
| Race (NIH/OMB) Baseline (Phase 2) Black or African American | 33 Participants |
| Race (NIH/OMB) Baseline (Phase 2) More than one race | 6 Participants |
| Race (NIH/OMB) Baseline (Phase 2) Native Hawaiian or Other Pacific Islander | 1 Participants |
| Race (NIH/OMB) Baseline (Phase 2) Unknown or Not Reported | 5 Participants |
| Race (NIH/OMB) Baseline (Phase 2) White | 14 Participants |
| Region of Enrollment United States | 100 participants |
| Sex: Female, Male Baseline (Phase 1) Female | 20 Participants |
| Sex: Female, Male Baseline (Phase 1) Male | 20 Participants |
| Sex: Female, Male Baseline (Phase 2) Female | 16 Participants |
| Sex: Female, Male Baseline (Phase 2) Male | 44 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 50 | 0 / 74 |
| other Total, other adverse events | 0 / 50 | 0 / 74 |
| serious Total, serious adverse events | 0 / 50 | 0 / 74 |